These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling. Hultberg A; Morello V; Huyghe L; De Jonge N; Blanchetot C; Hanssens V; De Boeck G; Silence K; Festjens E; Heukers R; Roux B; Lamballe F; Ginestier C; Charafe-Jauffret E; Maina F; Brouckaert P; Saunders M; Thibault A; Dreier T; de Haard H; Michieli P Cancer Res; 2015 Aug; 75(16):3373-83. PubMed ID: 26141862 [TBL] [Abstract][Full Text] [Related]
25. The hepatocyte growth factor (HGF)-MET receptor tyrosine kinase signaling pathway: Diverse roles in modulating immune cell functions. Ilangumaran S; Villalobos-Hernandez A; Bobbala D; Ramanathan S Cytokine; 2016 Jun; 82():125-39. PubMed ID: 26822708 [TBL] [Abstract][Full Text] [Related]
26. Stanniocalcin 1 is an autocrine modulator of endothelial angiogenic responses to hepatocyte growth factor. Zlot C; Ingle G; Hongo J; Yang S; Sheng Z; Schwall R; Paoni N; Wang F; Peale FV; Gerritsen ME J Biol Chem; 2003 Nov; 278(48):47654-9. PubMed ID: 14500721 [TBL] [Abstract][Full Text] [Related]
27. Cellular and molecular mechanisms of HGF/Met in the cardiovascular system. Gallo S; Sala V; Gatti S; Crepaldi T Clin Sci (Lond); 2015 Dec; 129(12):1173-93. PubMed ID: 26561593 [TBL] [Abstract][Full Text] [Related]
28. Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET. Greenall SA; Gherardi E; Liu Z; Donoghue JF; Vitali AA; Li Q; Murphy R; Iamele L; Scott AM; Johns TG PLoS One; 2012; 7(4):e34658. PubMed ID: 22511956 [TBL] [Abstract][Full Text] [Related]
29. Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30. Vigna E; Chiriaco C; Cignetto S; Fontani L; Basilico C; Petronzelli F; Comoglio PM Mol Oncol; 2015 Nov; 9(9):1760-72. PubMed ID: 26119717 [TBL] [Abstract][Full Text] [Related]
30. Crystal structure of the Sema-PSI extracellular domain of human RON receptor tyrosine kinase. Chao KL; Tsai IW; Chen C; Herzberg O PLoS One; 2012; 7(7):e41912. PubMed ID: 22848655 [TBL] [Abstract][Full Text] [Related]
31. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Kim KJ; Wang L; Su YC; Gillespie GY; Salhotra A; Lal B; Laterra J Clin Cancer Res; 2006 Feb; 12(4):1292-8. PubMed ID: 16489086 [TBL] [Abstract][Full Text] [Related]
32. Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy. Tong XM; Feng L; Suthe SR; Weng TH; Hu CY; Liu YZ; Wu ZG; Wang MH; Yao HP J Immunother Cancer; 2019 Sep; 7(1):250. PubMed ID: 31519211 [TBL] [Abstract][Full Text] [Related]
33. Mimics of the dimerization domain of hepatocyte growth factor exhibit anti-Met and anticancer activity. Kawas LH; Yamamoto BJ; Wright JW; Harding JW J Pharmacol Exp Ther; 2011 Nov; 339(2):509-18. PubMed ID: 21859930 [TBL] [Abstract][Full Text] [Related]
34. Anti-cancer approach with NK4: Bivalent action and mechanisms. Nakamura T; Sakai K; Nakamura T; Matsumoto K Anticancer Agents Med Chem; 2010 Jan; 10(1):36-46. PubMed ID: 20015005 [TBL] [Abstract][Full Text] [Related]
35. Identification of functional domains in the hepatocyte growth factor and its receptor by molecular engineering. Bardelli A; Ponzetto C; Comoglio PM J Biotechnol; 1994 Sep; 37(2):109-22. PubMed ID: 7765452 [TBL] [Abstract][Full Text] [Related]
36. Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-"decoy" strategy. Basilico C; Modica C; Maione F; Vigna E; Comoglio PM Int J Cancer; 2018 Oct; 143(7):1774-1785. PubMed ID: 29693242 [TBL] [Abstract][Full Text] [Related]
37. Impaired ligand-dependent MET activation caused by an extracellular SEMA domain missense mutation in lung cancer. Miao W; Sakai K; Sato H; Imamura R; Jangphattananont N; Takagi J; Nishita M; Minami Y; Matsumoto K Cancer Sci; 2019 Oct; 110(10):3340-3349. PubMed ID: 31342590 [TBL] [Abstract][Full Text] [Related]
38. Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma. Suzuki Y; Sakai K; Ueki J; Xu Q; Nakamura T; Shimada H; Nakamura T; Matsumoto K Int J Cancer; 2010 Oct; 127(8):1948-57. PubMed ID: 20104519 [TBL] [Abstract][Full Text] [Related]
39. Up-regulation of hepatocyte growth factor receptor: an amplification and targeting mechanism for hepatocyte growth factor action in acute renal failure. Liu Y; Tolbert EM; Lin L; Thursby MA; Sun AM; Nakamura T; Dworkin LD Kidney Int; 1999 Feb; 55(2):442-53. PubMed ID: 9987069 [TBL] [Abstract][Full Text] [Related]